Natera to Report its Third Quarter Results on November 5, 2026
Natera to Report its Third Quarter Results on November 5, 2026
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2026, after the market closes on November 5, 2026. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET.
Earnings Conference Call Information |
|||
Event: |
Natera’s Third Quarter 2026 Financial Results |
||
Date: |
November 5, 2026 |
||
Time: |
4:30 p.m. ET |
||
Live Dial-In: |
1-833-461-5787 (Domestic) |
||
|
1-585-542-9983 (International) |
||
Conference ID: |
221 556 643 |
||
Webcast: |
It is recommended that participants pre-register for the call. Pre-registration is available here.
A webcast replay will be available at investor.natera.com.
About Natera
Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261029604280/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
This Once-Hot AI Stock Now Looks Deeply Undervalued
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
What 7 Key Market Indicators Are Telling Investors Right Now
United States